(Q43662490)

25 November 2017

title

Role of cysteinyl leukotrienes in nociceptive and inflammatory conditions in experimental animals (English)

1 reference

25 November 2017

N K Jain

1

1 reference

25 November 2017

S K Kulkarni

series ordinal

2

1 reference

25 November 2017

A Singh

series ordinal

3

1 reference

25 November 2017

language of work or name

English

0 references

publication date

1 June 2001

1 reference

European Journal of Pharmacology

25 November 2017

published in

1 reference

25 November 2017

volume

423

1 reference

25 November 2017

issue

1

1 reference

25 November 2017

page(s)

85-92

1 reference

Ischemic acute renal failure and antioxidant therapy in the rat. The relation between glomerular and tubular dysfunction

25 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901083-4

Leukotriene receptor antagonists and biosynthesis inhibitors: potential breakthrough in asthma therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901083-4

7 January 2021

Zafirlukast (Accolate)

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901083-4

Influence of a long-acting bradykinin antagonist, Hoe 140, on some acute inflammatory reactions in the rat

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901083-4

Kinins and peritoneal exudates induced by carrageenin and zymosan in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901083-4

Anti-inflammatory, analgesic, antipyretic and related properties of meloxicam, a new non-steroidal anti-inflammatory agent with favourable gastrointestinal tolerance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901083-4

Clinical activity of leukotriene inhibitors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901083-4

Lipid mediators in inflammatory disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901083-4

Leukotriene D4 depresses the mechanosensitivity of group III and IV muscle receptors in the rat

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901083-4

Modulation of acute inflammation by endogenous nitric oxide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901083-4

Leukotriene B4Produces Hyperalgesia That Is Dependent on Polymorphonuclear Leukocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901083-4

The effect of leukotriene synthesis inhibitors in models of acute and chronic inflammation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901083-4

Lipid mediators produced through the lipoxygenase pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901083-4

Lornoxicam, a new potent NSAID with an improved tolerability profile

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901083-4

Melatonin reversal of lipopolysacharides-induced thermal and behavioral hyperalgesia in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901083-4

Montelukast in the prophylaxis of migraine: a potential role for leukotriene modifiers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901083-4

Synthesis and biological evaluation of 5-[[3,5-bis(1,1-dimethylethyl)- 4-hydroxyphenyl]methylene]oxazoles, -thiazoles, and -imidazoles: novel dual 5-lipoxygenase and cyclooxygenase inhibitors with antiinflammatory activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901083-4

Recent innovations in asthma therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901083-4

Pharmacotherapy of asthma in children, with special reference to leukotriene receptor antagonists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901083-4

Cyclooxygenase isoenzymes and newer therapeutic potential for selective COX-2 inhibitors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901083-4

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0014-2999(01)01083-4

1 reference

25 November 2017

1 reference